PHOO Stock Overview
Engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Photocure ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 57.70 |
| 52 Week High | NOK 57.70 |
| 52 Week Low | NOK 56.70 |
| Beta | 0.66 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -38.16% |
| 5 Year Change | 22.12% |
| Change since IPO | 70.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHOO | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 5.0% | 2.2% |
| 1Y | n/a | 2.5% | 8.8% |
Return vs Industry: Insufficient data to determine how PHOO performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how PHOO performed against the UK Market.
Price Volatility
| PHOO volatility | |
|---|---|
| PHOO Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: PHOO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHOO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 88 | Dan Schneider | www.photocure.com |
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix.
Photocure ASA Fundamentals Summary
| PHOO fundamental statistics | |
|---|---|
| Market cap | NOK 1.79b |
| Earnings (TTM) | -NOK 33.69m |
| Revenue (TTM) | NOK 462.30m |
3.9x
P/S Ratio-53.3x
P/E RatioIs PHOO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHOO income statement (TTM) | |
|---|---|
| Revenue | NOK 462.30m |
| Cost of Revenue | NOK 25.87m |
| Gross Profit | NOK 436.44m |
| Other Expenses | NOK 470.13m |
| Earnings | -NOK 33.69m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.24 |
| Gross Margin | 94.41% |
| Net Profit Margin | -7.29% |
| Debt/Equity Ratio | 0% |
How did PHOO perform over the long term?
See historical performance and comparison